Mobile CT screening starts bringing early lung cancer detection into Leeds communities
A new lung cancer screening service is now reaching people in Leeds who face the highest risk of disease, with the goal of inviting about 90,000 residents over the next two years. Free NHS checks are being offered to adults aged 55 to 74 who smoke or have smoked in the past, using a mobile CT scanner that will move between local sites rather than requiring patients to travel to a hospital-based imaging department.
The first scans began at White Rose Shopping Centre in Beeston, a deliberately visible setting that reflects a central idea behind screening medicine: when a cancer often causes no symptoms until it is advanced, diagnosis has to move closer to the community. Lung cancer remains one of the deadliest malignancies in Yorkshire, and Leeds Teaching Hospitals NHS Trust says deaths from the disease are double those from breast and prostate cancer. In practical terms, that makes earlier detection more than a service expansion; it is an attempt to intercept a disease that often arrives silently and late.
One of the first patients scanned was 71-year-old David Barraclough, a former smoker who has had three bouts of pneumonia. His experience captures why screening programmes are built around risk rather than symptoms alone. A persistent cough, repeated chest infections, unexplained breathlessness, or a history of tobacco exposure can all sit behind a long period of clinical uncertainty, and low-dose CT is designed to identify suspicious lesions before they declare themselves through pain, obstruction, or metastatic spread.
Why the programme is built around smoking history and silent disease
The eligibility criteria are tightly drawn: people aged 55 to 74 who currently smoke or have ever smoked cigarettes in Leeds will be invited over the next couple of years. After an invitation letter, eligible residents are offered a telephone consultation. Those at high risk are then sent for a low-dose CT scan at the mobile unit.
That sequence matters because the benefit of lung cancer screening depends on targeting the group most likely to harbor early disease while avoiding indiscriminate scanning. Tobacco exposure remains the dominant risk factor for lung cancer, and a structured invitation process is intended to capture people who might otherwise delay care until symptoms become impossible to ignore. CT screening does not prevent cancer from forming; it changes the stage at which disease is found, and stage shift is the whole point of screening in a cancer where early tumors can be surgically treated or managed with far better outcomes than advanced disease.
The Leeds Lung Health Check trial provides the local foundation for this rollout. Between 2018 and 2024, the trial screened 8,800 people and detected more than 400 cancers, most at an early stage. Those numbers explain why the service is being expanded beyond research into routine care. A programme that finds a large number of cancers before symptoms appear is not simply identifying disease more often; it is finding disease at a point when treatment options are still likely to be meaningful.
There is also a systems-level reason for the mobile format. By positioning the scanner in community settings, the programme lowers logistical barriers that can keep high-risk people from attending hospital appointments. The units are designed with stairs and lift access, and radiography teams will operate the scans six days a week. Convenience is not a cosmetic feature here. For a screening programme, missed appointments and poor uptake can blunt the clinical benefit as surely as a weak test can.
A local trial moved into a wider service after finding cancers early
The Leeds programme was funded by Yorkshire Cancer Research and delivered with Leeds Teaching Hospitals NHS Trust and the University of Leeds. Alliance Medical is supporting the service by providing the mobile imaging units and radiography teams. The structure is important because lung cancer screening requires more than a scan; it also needs imaging expertise, referral pathways, and the capacity to follow up abnormal findings without long delays.
The NHS plans to fully roll out the national lung screening programme by 2030, and Leeds now sits among the early examples of how that policy is being translated into routine care. Screening is likely to matter most in places where disease burden is high and access gaps persist. Suzanne Rogerson, lead nurse for the Leeds Lung Cancer Screening Programme, described the mobile model as a way to improve access and reduce health inequalities across the city. Her point reflects the central tension in screening: the people at greatest risk are often the least likely to reach specialist services quickly, especially when symptoms are mild, intermittent, or easy to dismiss.
A direct clinical warning remains attached to the invitation-only model. People who already have breathing problems or a cough that will not go away are being urged to contact their GP immediately rather than waiting for a screening letter. Screening is for asymptomatic people at elevated risk; it is not a substitute for diagnostic assessment when symptoms are already present. That distinction is critical, because a patient with established symptoms needs evaluation for existing disease, not enrollment in a preventive pathway designed to detect early lesions before they announce themselves.
For Leeds, the immediate test is not whether the scanner can operate in a shopping center car park. It is whether the programme can consistently reach the people most exposed to tobacco-related risk, identify disease before it becomes incurable, and keep diagnostic follow-up moving fast enough to convert early detection into treatment. The trial has already shown that early cancers can be found in this population. The new service now has to prove that community-based screening can deliver that same result at scale.
The article does not provide a breakdown of interval cancers, false positives, downstream procedures, or longer-term survival, so those questions remain open in this rollout. The operational challenge now is whether the invitation pathway, mobile imaging model, and follow-up system can hold together across thousands of eligible residents over the next two years.